THERAPY DOSSIER · th-255770e19fbf

Pamidronate

Drug · INHIBITOR of farnesyl diphosphate synthase; binds bone hydroxyapatite and is released during resorption, taken up by osteoclasts, inhibiting protein prenylation of GTPases required for ruffled-border formation (ChEMBL mec_id 1051). ATC M05BA03.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: INHIBITOR of farnesyl diphosphate synthase; binds bone hydroxyapatite and is released during resorption, taken up by osteoclasts, inhibiting protein prenylation of GTPases required for ruffled-border formation (ChEMBL mec_id 1051). ATC M05BA03.
Target: CHEMBL1782
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: 1991
Development stage: Not recorded
ChEMBL record: CHEMBL834 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Pamidronate; Pamidronic acid; Pamidronate disodium; Aredia; CGP-23339AE
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00738257 ↗PHASE4completed

Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients

Bone Loss

Enrolment: 126 · Results not recorded

NCT02721433 ↗PHASE4completed

4-weekly Versus 12-weekly Bone-targeted Agents in Bone Metastases (REaCT-BTA)

Breast Cancer · Prostate Cancer · Metastasis

Enrolment: 263 · Results not recorded

NCT00005901 ↗PHASE3completed

A Trial of Pamidronate in Children With Osteogenesis Imperfecta

Osteogenesis Imperfecta

Enrolment: 34 · Results not recorded

NCT01210599 ↗PHASE1/PHASE2completed

A Pilot Trial of Intravenous Pamidronate for Low Back Pain

Chronic Low Back Pain

Enrolment: 44 · Results not recorded

NCT00022841 ↗PHASE1/PHASE2terminated

Prevention of Steroid-Induced Osteoporosis in Children

Osteoporosis

Enrolment: 40 · Results not recorded

NCT02544659 ↗PHASE1completed

Long Term Efficacy of IV Bisphosphonates for Bone Marrow Edema in SAPHO Syndrome

SAPHO Syndrome

Enrolment: 30 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27889760 ↗2016Mixed findings

Pamidronate Attenuates Oxidative Stress and Energetic Metabolism Changes but Worsens Functional Outcomes in Acute Doxorubicin-Induced Cardiotoxicity in Rats.

RatChemical/toxinWistarMalen = 64 male Wistar rats allocated to four groupsIntraperitonealPamidronate 3 mg/kg intraperitoneally; doxorubicin 20 mg/kg…Pamidronate given 24 h before doxorubicin; animals killed 48 h after doxorubicin

Model: Acute doxorubicin-induced cardiotoxicity, single doxorubicin injection 20 mg/kg intraperitoneally

Pamidronate attenuated oxidative stress and improved myocardial energetic metabolism but worsened systolic function, with lower left ventricular ejection fraction and lower +dP/dt in the doxorubicin plus pamidronate group, alongside serum hypocalcaemia. The authors do not recommend its use with ant…

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…